Actelion starts Phase IIb trial with MS drug
This article was originally published in Scrip
Executive Summary
Actelion has started dosing multiple sclerosis (MS) patients with the first S1P1-receptor-selective agonist, ACT-128800 (also known as RG3477), in a Phase IIb trial. The move has triggered a $20 million payment from Roche, who is collaborating in the development of the drug.